Ayala Pharmaceuticals, Inc. Common Stock
AYLA
AYLA was delisted on the 18th of January, 2023.
12 hedge funds and large institutions have $20.9M invested in Ayala Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
9% more funds holding
Funds holding: 11 → 12 (+1)
0.04% less ownership
Funds ownership: 15.54% → 15.5% (-0.04%)
1% less capital inflows, than outflows
Capital inflows: $1.45M | Capital outflows: $1.46M
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$544K |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$506K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$240K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$107K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$44.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.18M |
| 2 |
Millennium Management
New York
|
-$135K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$48.1K |
| 4 |
Morgan Stanley
New York
|
-$39.2K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$31.2K |
AYLA Hedge Fund Activity: Q2 2021 in Review
12 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Ayala Pharmaceuticals, Inc. Common Stock (AYLA) for Q2 2021, worth a combined $20.9M — down 6.3% from $22.3M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AYLA positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Sio Capital Management, adding an estimated $544K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.18M sold.
- 12 institutional investors held Ayala Pharmaceuticals, Inc. Common Stock (AYLA) as of Q2 2021, up from 11 in Q1 2021.
- Funds reported $20.9M of Ayala Pharmaceuticals, Inc. Common Stock stock for Q2 2021, down 6.3% quarter-over-quarter.
- 4 funds opened new Ayala Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 3 closed out, a net change of +1 holder.
- The largest Ayala Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was Sio Capital Management, an estimated $544K added.
- The largest Ayala Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was Opaleye Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q2 2021.